Altawalbeh SM, Wateska AR, Patricia Nowalk M, Lin CJ, et al. Corrigendum to "Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older" [Vaccine 42 (2024) 3024-3032]. Vaccine 2024 Jul 15:S0264-410X(24)00789-8. doi: 10.1016/j.vaccine.2024.
PMID: 39013693